A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study

Type 2 Diabetes

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study

Diabetes Obes Metab.

Frias JP, Zimmer Z, Lam RLH, Lic GA, Ntabadde C, Iredale C, O'Neill EA2, Engel SS, Kaufman KD, Makimura H, Crutchlow MF

doi: 10.1111/dom.13626.

COMMENTED

Type 2 Diabetes

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study

Diabetes Obes Metab.

Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, O'Neill EA, Engel SS, Kaufman KD, Makimura H, Crutchlow MF

doi: 10.1111/dom.13626.

Diabetes - GeneralType 2 Diabetes

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Diabetes Obes Metab.

Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S

doi: 10.1111/dom.12892.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Diabetes Care.

Jabbour SA, Frìas JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C

doi: 10.2337/dc18-0680.

COMMENTED

Type 1 Diabetes

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.1111/dom.14060.

Type 2 DiabetesGlycemic Control

Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial

Diabetes Obes Metab.

Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, Cardona S, Peng L, Pasquel FJ, Umpierrez GE; Linagliptin Inpatient Research Group

doi: 10.1111/dom.13587.

Type 2 DiabetesGlycemic Control

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Diabetes Obes Metab.

Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J

doi: 10.1111/dom.13594.

COMMENTED

Type 2 Diabetes

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study

Diabetes Obes Metab.

Roussel R, Durán García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS

doi: 10.1111/dom.13574.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials

Diabetes Technol Ther.

Sun D, Zhang X, Hou XX

doi: 10.1089/dia.2018.0132.

Related content

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial

Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study

Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials